Vγ9Vδ2 T cells expressing a BCMA—Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth
Overview
This study generates BCMA-CAR Vg9Vd2 T cells via mRNA electroporation. Vg9Vd2 T cells were expanded using Zometa and co-cultured with aAPCs. Previous work by the group used G-Rex® vessels for large-scale expansion.
What this paper found
Transient mRNA electroporation of a first-generation BCMA CAR (αBCMAz) into ex vivo expanded Vγ9Vδ2 T cells produced potent, antigen-specific anti-myeloma activity in vitro and in vivo. Transfection efficiency reached 70% to 86%, with CAR expression peaking one day after electroporation and becoming hardly detectable by day 6. The modified cells lysed BCMA-positive KMS-11, KMS-18, OPM-2 and U266 lines more strongly than NKG2Dz CAR cells, released IFN-γ and mobilised CD107a only against BCMA-positive targets. In KMS-11-Luc xenografted NSG mice given Zometa plus weekly doses of 1 × 10^7 cells for three weeks, femur radiance fell from 8.1 × 10^7 and 6.0 × 10^7 to 2.3 × 10^7, and median survival rose from 32.5 and 41 to 55 days.
Note: The authors note that the treatment retarded tumor growth and improved survival but did not eradicate established tumors or induce tumor regression.
Our finding, for the first time, provides clear experimental evidence that Vγ9Vδ2 T cells modified with a CAR can result in notable therapeutic outcomes for MM bone lesions. — Xi Zhang, Yu Yang Ng, Zhicheng Du, Zhendong Li, Can Chen, Lin Xiao, Wee Joo Chng, Shu Wang, PLOS ONE
Study details
- Authors
- Xi Zhang, Yu Yang Ng, Zhicheng Du, Zhendong Li, Can Chen, Lin Xiao, Wee Joo Chng, Shu Wang
- Institution
- Department of Biological Sciences, National University of Singapore, Singapore, Singapore · Department of Haematology-Oncology, National University Cancer Institute Singapore, National University Health System, Singapore, Singapore · Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore · Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- Journal
- PLOS ONE
- Year
- 2022
- Cell type(s)
- CAR T Cells, γδ T
- Application area
- Hematologic malignancy
- Study phase
- Preclinical
Explore related
Full citation
Zhang X, Ng YY, Du Z, et al. Vγ9Vδ2 T cells expressing a BCMA—Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth. PLoS One. 2022;17(6):e0267475.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.